Research programme: T cell engager immunotherapies - Boehringer Ingelheim

Alternative Names: T cell engager based anticancer therapeutics -Boehringer Ingelheim

Latest Information Update: 16 Jun 2022

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Boehringer Ingelheim
Class Antibodies; Antineoplastics; Immunotherapies; Recombinant fusion proteins
Mechanism of Action T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

03 Jun 2022 Boehringer Ingelheim in-licenses innovative antibodies from Agency for Science, Technology and Research
03 Jun 2022 Early research in Cancer in Germany (Parenteral) in June 2022

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com